The Era of Artificial Intelligence, Machine Learning and Data Science in the Pharmaceutical Industry examines the drug discovery process, assessing how new technologies have improved effectiveness. Artificial intelligence and machine learning are considered the future for a wide range of disciplines and industries, including the pharmaceutical industry. In an environment where producing a single approved drug costs millions and takes many years of rigorous testing prior to its approval, reducing costs and time is of high interest. This book follows the journey that a drug company takes when producing a therapeutic, from the very beginning to ultimately benefitting a patient's life. This comprehensive resource will be useful to those working in the pharmaceutical industry, but will also be of interest to anyone doing research in chemical biology, computational chemistry, medicinal chemistry and bioinformatics.

The Design and Development of Novel Drugs and Vaccines: Principles and Protocols presents both in silico methods and experimental protocols for vaccine and drug design and development, critically reviewing the most current research and emphasizing approaches and technologies that accelerate and lower the cost of product development. Sections review the technologies and approaches used to identify, characterize and establish a protein as a new drug and vaccine target, cover several molecular methods for in vitro studies of the desired target, and present various physiological parameters for in vivo studies. The book includes preclinical trials and research, along with information on FDA approval.

The Side Effects of Drugs Annual was first published in 1977. It has been continually published since then, as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each new Annual continues to provide clinicians and medical investigators with a reliable and critical yearly survey of new data and trends in the area of Adverse Drug Reactions and Interactions. An international team of specialists has contributed to the informative, by critically interpreting it, and by pointing to whatever is misleading.

*Provides a critical yearly survey of new data and trends *Special reviews in this Annual include, among other topics: Epidemiology of the use of ecstasy, Paracetamol and the risk of asthma, Combination vaccines/multiple immunizations, Interactions of herbal medicines with warfarin, and Tyrosine kinase inhibitors.

Delivery of therapeutic proteomics and genomics represent an important area of drug delivery research. Genomics and proteomics approaches could be used to direct drug development processes by unearthing pathways involved in disease pathogenesis where intervention may be most successful.

This book describes the basics of genomics and proteomics and highlights the various chemical, physical and biological approaches to protein and gene delivery.
Covers a diverse array of topics from basic sciences to therapeutic applications of proteomics and genomics deliveryOf interest to researchers in both academia and industryHighlights what s currently known and where further research is needed"

Without warning stroke can paralyze, blind, or kill. Some victims recover, but many do not and may even suffer another disabling or fatal attack. The drug known as tPA can drastically reduce the long-term disability associated with stroke, but despite its near-miraculous capabilities and the growing support of most neurologists, it has been slow to win acceptance as the standard of care in emergency departments nationwide.
tPA for Stroke chronicles how this remarkable drug came to be tested in stroke victims, its early years in development by the pharmaceutical giant Genentech, and its eventual marginalization due to a convergence of unfavorable political, fiscal, and medical circumstances. For instance, initially many stroke specialists were unconvinced that the drug's benefits outweigh its risks (tPA was originally developed and is still used for cardiac patients). Moreover, neurologists called upon to assess stroke patients have not typically been trained to make decisions in emergency settings--and tPA must be given within a scant few hours after stroke. These and other factors have continued to delay the drug's universal acceptance as the most effective treatment available, and to hamper the general public's awareness that such a treatment exists--a troubling state of affairs that Zivin and Simmons argue must be rectified. Instilling the knowledge that anyone, at any time, is susceptible to stroke, from the old and infirm to the young and healthy, tPA for Stroke is a clarion call to awareness in a rapidly changing healthcare environment in which stroke, long a disease in thrall to resignation and pessimism, must be neglected no longer.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
There has been significant progress in the development of targeted therapy drugs that act specifically on certain cancers, and that minimize damage to normal cells. Oncologists and cancer researchers will rely on this volume to determine effective drug treatments.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only anticancer drugs, but also all other drugs that act upon related organ systems affected by cancer
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

*Presents the latest research in the field of drug discovery *Publishes on a twice yearly basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect

Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona Pandemic presents a selection of updated chapters from Re-Engineering Clinical Trials that feature innovative options and methods in clinical trials. The Coronavirus pandemic is an accelerator for digitalization in many industries, including clinical trials. This book considers best practices, alternative study concepts requiring fewer patients, studies with less patient interaction, the design of "virtualized" protocols, and moving from data to decisions. This book will be helpful to pharmacologists, physicians and clinical researchers involved in the process of clinical development and clinical trial design.

Elsevier now offers a series of derivative works based on the acclaimed "Meyler s Side Effect of Drugs, 15th Edition." These individual volumes are grouped by specialty to benefit the practicing biomedical researcher and/or clinician.
This volume is essential for internal medicine physicians and general practitioners who prescribe antibiotic drugs, like penicillin and tetracycline that cure bacterial infections, and antiviral drugs used to treat patients with HIV and herpes viruses.
* The only drug guide that includes clinical case studies and expert analysis
* "UNIQUE " Features not only antimicrobial drugs, but also all other drugs that act in an anti-microbial manner
* Most complete cross referencing of drug-drug interactions available
* Latest content from the most highly regarded compilation of drug side effects: "Side Effects of Drugs Annual" serial"

Inhaled medicines are widely used to treat pulmonary and systemic diseases. The efficacy and safety of these medicines can be influenced by the deposited fraction, the regional deposition pattern within the lungs and by post-depositional events such as drug dissolution, absorption and clearance from the lungs. Optimizing performance of treatments thus requires that we understand and are able to quantify these product and drug attributes. Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches explores the current state of the art with respect to inhalation drug delivery, technologies available to assess product performance, and novel in silico methods now available to link in vitro product performance to clinical performance. Recent developments in the latter field, especially the prospect of integration of three-dimensional Computational Fluid Particle Methods (3D-CFPD) with physiologically based pharmacokinetic (PBPK models), unlocks the potential for in silico population studies that can help inform and optimize treatment and product development strategies. In this highly multidisciplinary field, where progress occurs at the intersection of several disciplines of engineering and science, this work aims to integrate current knowledge and understanding and to articulate a clear vision for future developments.

Nanotechnology for Oral Drug Delivery: From Concept to Applications discusses the current challenges of oral drug delivery, broadly revising the different physicochemical barriers faced by nanotechnolgy-based oral drug delivery systems, and highlighting the challenges of improving intestinal permeability and drug absorption. Oral delivery is the most widely used form of drug administration due to ease of ingestion, cost effectiveness, and versatility, by allowing for the accommodation of different types of drugs, having the highest patient compliance. In this book, a comprehensive overview of the most promising and up-to-date engineered and surface functionalized drug carrier systems, as well as opportunities for the development of novel and robust delivery platforms for oral drug administration are discussed. The relevance of controlling the physicochemical properties of the developed particle formulations, from size and shape to drug release profile are broadly reviewed. Advances in both in vitro and in vivo scenarios are discussed, focusing on the possibilities to study the biological-material interface. The industrial perspective on the production of nanotechnology-based oral drug delivery systems is also covered. Nanotechnology for Oral Drug Delivery: From Concept to Applications is essential reading for researchers, professors, advanced students and industry professionals working in the development, manufacturing and/or commercialization of nanotechnology-based systems for oral drug delivery, targeted drug delivery, controlled drug release, materials science and biomaterials, in vitro and in vivo testing of potential oral drug delivery technologies.

Over the past few decades, there has been unprecedented progress in the design of versatile biopolymer-based nanoplatforms for pharmaceutical and biomedical applications, particularly due to their attractive traits, including excellent biocompatibility, outstanding biodegradability, low immunogenicity, and facile chemical modifiability. Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications serves as a clear and detailed body of information on the synthesis and characterization of biopolymer-based materials in nanomedicine. This book describes various nanomaterials consisting of biopolymers including polysaccharides (i.e., derived from plants, animals, bacteria, algae, and fungi) and polypeptides in terms of their structures, synthetic protocols, and characterization and uses as therapeutic drugs and gene delivery carriers and in other biomedical fields. The chapters of this book, which are contributed by internationally renowned scholars working in the arena of biopolymer-based nanomaterials, would offer a wide vision on the potential future applications of these nanomaterials in the delivery and targeting of bioactive molecules of pharmaceutical interests and in tissue engineering, biosensing, bioimaging, and diagnostic purposes. The state-of-the-art information presented in the book would also encourage young investigators and researchers to further bring cutting-edge developments in the field of nanomedicine in the near future.

Taxaceae and Cephalotaxaceae: Biodiversity, Chemodiversity, and Pharmacotherapy accounts for the biodiversity and chemodiversity of these medicinal plants, examining and synthesizing existing research into their biology, chemistry and pharmacotherapy. The title examines how pharmacophylogeny allows sustainable conservation and exploitation, presents how these plants work from the chemical level upward, and examines associated microbe compounds. Chapters present a summary of biological and biochemical research of Taxaceae plants, progress in mining their chemodiversity, mining pharmacotherapy utility from their chemodiversity and biodiversity, drug metabolism and pharmacokinetic diversity of their medicinal compounds, mining pharmacotherapy utility from associated microbes, and more. Sections cover the biodiversity, chemodiversity and pharmacotherapy of Cephalotaxus medicinal plants, Amentotaxus, Pseudotaxus and Torreya medicinal plants. The book envisages that multiple omics platforms and advanced systems biology will allow further exploration of Taxaceae and Cephalotaxaceae, thus streamlining the future drug supply chain.

This book is a history of medicines and the commercial actors that make and sell them, covering the 140 years since the modern pharmaceutical industry came into being. It is written in a lively and accessible way, aiming at a general audience that combines historical narrative with fascinating case studies on drug discovery and commercialization, from the rat poison that became warfarin, to a cardiovascular treatment that was turned into Viagra. In a non-partisan way it also examines some of the less noble manifestations of corporate behavior, concluding with an agenda for reform.It is hard to think of anything nobler than to bring to the world a medicine that saves lives. And over 140 years of history, the pharmaceutical industry has produced a range of remarkable products, albeit typically with external scientific and financial support. Making medicines is a very big and profit-driven business, and the industry does not always make the right products for the right people, or at the right prices.The industry wields immense power over lives and economies. How has it risen to this position of dominance? Are the interests of the industry and the public in balance? What should we admire about the industry? What should we criticise and seek to change? The importance of this book lies in the fact that we are all stakeholders in this industry whether or not we own shares, so we all need answers to these questions.Related Link(s)